NGM Biopharmaceuticals, Inc

Add to watchlist
€13.9
Last updated:06/09/2021
0IK: F
NGM Biopharmaceuticals, Inc

NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fi… Show more

P/E ratio
-

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-14.159M
-493K
+96.52%
-42.795M
-8580.53%
-102.487M
-139.48%
Cashflow
Sum up money going in and out company
-17.413M
-7.597M
+56.37%
-41.174M
-441.98%
-83.496M
-102.79%
Total liabilities
All combined debts and obligations
369.919M
59.208M
-83.99%
49.684M
-16.09%
49M
-1.38%
Company profile
CEO
Dr. David J. Woodhouse
Market capitalization
Small (1.15B)